EZH2的过表达与慢性淋巴细胞白血病的不良预后相关。

Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.

作者信息

Rabello Doralina do Amaral, Lucena-Araujo Antonio Roberto, Alves-Silva Juliana Carvalho Rocha, da Eira Vinícius Burnett Aboud Souza, de Vasconcellos Maria Catarina Cals, de Oliveira Fábio Morato, Rego Eduardo Magalhaes, Saldanha-Araujo Felipe, Pittella Silva Fábio

机构信息

Laboratory of Molecular Pathology of Cancer, University of Brasília, Av. L2 Norte, Brasília, DF 70.910-900, Brazil.

Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP 14.048-900, Brazil.

出版信息

Blood Cells Mol Dis. 2015 Jan;54(1):97-102. doi: 10.1016/j.bcmd.2014.07.013. Epub 2014 Aug 15.

DOI:10.1016/j.bcmd.2014.07.013

PMID:25131810

Abstract

EZH2, a histone methyltransferase, is overexpressed in several human tumors, but whether it exerts any impact in chronic lymphocytic leukemia (CLL) remains unknown. We used real time PCR to investigate the expression profile of EZH1 and EZH2 in 59 CLL patients, 10 samples of purified B-cells from healthy donors and 12 normal adult tissues. EZH2 was overexpressed in CLL patients and correlates with high white blood cell count, ZAP-70 expression and chromosomal abnormalities. EHZ1 expression does not correlate with CLL progression. EZH2 overexpression is related to a poor prognosis of CLL and could be a useful tool to assess its aggressiveness.

摘要

组蛋白甲基转移酶EZH2在多种人类肿瘤中过表达，但它是否对慢性淋巴细胞白血病（CLL）有任何影响仍不清楚。我们使用实时PCR研究了59例CLL患者、10份来自健康供体的纯化B细胞样本和12个正常成人组织中EZH1和EZH2的表达谱。EZH2在CLL患者中过表达，且与高白细胞计数、ZAP-70表达和染色体异常相关。EHZ1表达与CLL进展无关。EZH2过表达与CLL的不良预后相关，可能是评估其侵袭性的有用工具。